K. Lorizzo

419 total citations
20 papers, 227 citations indexed

About

K. Lorizzo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, K. Lorizzo has authored 20 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in K. Lorizzo's work include Neuroendocrine Tumor Research Advances (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Research Studies (5 papers). K. Lorizzo is often cited by papers focused on Neuroendocrine Tumor Research Advances (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Research Studies (5 papers). K. Lorizzo collaborates with scholars based in Italy, Norway and Hungary. K. Lorizzo's co-authors include Nicola Fazio, Filippo de Braud, Saverio Cinieri, Franco Nolè, Maria Giulia Zampino, S. Boselli, Marco Colleoni, Laura Zorzino, Giuseppina Sanna and Aron Goldhirsch and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

K. Lorizzo

19 papers receiving 225 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Lorizzo Italy 7 155 85 75 45 36 20 227
Noah Graham United States 9 205 1.3× 39 0.5× 137 1.8× 100 2.2× 39 1.1× 26 290
Silvia Fanello Italy 7 86 0.6× 32 0.4× 45 0.6× 22 0.5× 44 1.2× 17 204
R. Allerton United Kingdom 8 78 0.5× 86 1.0× 28 0.4× 10 0.2× 19 0.5× 10 203
Naoto Kitahara Japan 11 173 1.1× 259 3.0× 27 0.4× 17 0.4× 50 1.4× 23 325
Hamzeh Albaba Canada 6 113 0.7× 67 0.8× 38 0.5× 29 0.6× 11 0.3× 11 152
S. Andrew Peng United States 7 184 1.2× 142 1.7× 22 0.3× 8 0.2× 18 0.5× 17 283
Michelle F. Jacobs United States 8 68 0.4× 78 0.9× 20 0.3× 9 0.2× 45 1.3× 35 235
T.C. Kok Netherlands 9 203 1.3× 82 1.0× 119 1.6× 29 0.6× 58 1.6× 12 284
Ibrahim Elghissassi Morocco 8 100 0.6× 72 0.8× 77 1.0× 5 0.1× 31 0.9× 30 229
Valeria Stati Italy 11 182 1.2× 99 1.2× 24 0.3× 9 0.2× 27 0.8× 25 319

Countries citing papers authored by K. Lorizzo

Since Specialization
Citations

This map shows the geographic impact of K. Lorizzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Lorizzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Lorizzo more than expected).

Fields of papers citing papers by K. Lorizzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Lorizzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Lorizzo. The network helps show where K. Lorizzo may publish in the future.

Co-authorship network of co-authors of K. Lorizzo

This figure shows the co-authorship network connecting the top 25 collaborators of K. Lorizzo. A scholar is included among the top collaborators of K. Lorizzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Lorizzo. K. Lorizzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Curigliano, Giuseppe, Carmen Belli, Ilaria Colombo, et al.. (2024). 26O Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors. ESMO Open. 9. 102354–102354.
2.
Mach, Nicolas, Carmen Belli, Eduardo Fernández, et al.. (2023). 1037P Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors. Annals of Oncology. 34. S629–S630. 2 indexed citations
3.
4.
5.
Jérusalem, Guy, Gabriella Mariani, Miguel Martín, et al.. (2015). Everolimus in combination with Exemestane in hormone receptor-positive, locally advanced or metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors (NSAIs) : BALLET study (CRAD001YIC04). Open Repository and Bibliography (University of Liège). 75(9). 1 indexed citations
6.
Volante, Marco, Nadia Birocco, G. Gatti, et al.. (2013). Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Human Pathology. 45(4). 665–673. 25 indexed citations
7.
Spada, Francesca, et al.. (2012). Clinical Response after Sorafenib for Hepatocellular Carcinoma in Elderly Patients: A Report of Two Cases. Tumori Journal. 98(2). e53–e56. 1 indexed citations
8.
Fazio, Nicola, Saverio Cinieri, K. Lorizzo, et al.. (2010). Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treatment Reviews. 36. S87–S94. 27 indexed citations
9.
Meglio, Giovanni Di, Francesca Spada, Silvia Terzi, et al.. (2010). Metronomic capecitabine in advanced well or moderately differentiated neuroendocrine carcinomas.. Journal of Clinical Oncology. 28(15_suppl). e13130–e13130. 3 indexed citations
10.
Meglio, Giovanni Di, Cristian Massacesi, Davide Radice, et al.. (2010). Carboplatin with etoposide in patients with extrapulmonary “aggressive” neuroendocrine carcinoma.. Journal of Clinical Oncology. 28(15_suppl). e13072–e13072. 5 indexed citations
11.
Curigliano, Giuseppe, Giosafat Spitaleri, Elisabetta Magni, et al.. (2009). Cisplatin, Etoposide and Continuous Infusion Bleomycin in Patients with Testicular Germ Cell Tumors: Efficacy and Toxicity Data from a Retrospective Study. Journal of Chemotherapy. 21(6). 687–692. 6 indexed citations
12.
Lorizzo, K., Nicola Fazio, Davide Radice, et al.. (2008). Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemotherapy and Pharmacology. 64(2). 301–306. 11 indexed citations
13.
Fazio, Nicola, et al.. (2008). Miliary Hepatic Metastases from Neuroendocrine Carcinoma. Digestive Surgery. 25(5). 330–330. 6 indexed citations
14.
Zampino, Maria Giulia, Elena Magni, Cristian Massacesi, et al.. (2007). First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first‐line treatment for metastatic colorectal cancer. Cancer. 110(4). 752–758. 26 indexed citations
15.
Fazio, Nicola, Giuseppe Petralia, Patrizia Mancuso, et al.. (2007). Thalidomide in patients with advanced hepatocellular carcinoma: A clinical/biological study. Journal of Clinical Oncology. 25(18_suppl). 15076–15076. 1 indexed citations
16.
Sanna, Giuseppina, K. Lorizzo, Nicole Rotmensz, et al.. (2006). Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. Annals of Oncology. 18(2). 288–292. 40 indexed citations
17.
Zampino, Maria Giulia, K. Lorizzo, Andrea Rocca, et al.. (2006). Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer.. PubMed. 26(3B). 2425–8. 4 indexed citations
18.
Leonardi, Maria Cristina, Maria Giulia Zampino, Fabrizio Luca, et al.. (2006). Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer: a phase II study.. PubMed. 26(3B). 2419–23. 2 indexed citations
19.
Zampino, Maria Giulia, K. Lorizzo, Cristian Massacesi, et al.. (2005). First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer. Journal of Clinical Oncology. 23(16_suppl). 3659–3659. 19 indexed citations
20.
Fazio, Nicola, Franco Nolè, K. Lorizzo, et al.. (2004). Irinotecan combined with infusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemotherapy. Journal of Clinical Oncology. 22(14_suppl). 4146–4146. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noah Graham Breakdown of academic impact, for papers by Silvia Fanello Breakdown of academic impact, for papers by R. Allerton Breakdown of academic impact, for papers by Naoto Kitahara Breakdown of academic impact, for papers by Hamzeh Albaba Breakdown of academic impact, for papers by S. Andrew Peng Breakdown of academic impact, for papers by Michelle F. Jacobs Breakdown of academic impact, for papers by T.C. Kok Breakdown of academic impact, for papers by Ibrahim Elghissassi Breakdown of academic impact, for papers by Valeria Stati
Rankless by CCL
2026